Renoprotective Effects of Mangiferin: Pharmacological Advances and Future Perspectives

Sumaya Akter, Akhi Moni, Golam Mahbub Faisal, Muhammad Ramiz Uddin, Nourin Jahan, Md Abdul Hannan, Asadur Rahman and Md Jamal Uddin
Additional contact information
Sumaya Akter: ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh
Akhi Moni: ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh
Golam Mahbub Faisal: ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh
Muhammad Ramiz Uddin: ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh
Nourin Jahan: Department of Pharmacology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Takamatsu 761-0793, Japan
Md Abdul Hannan: ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh
Asadur Rahman: Department of Pharmacology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Takamatsu 761-0793, Japan
Md Jamal Uddin: ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh

IJERPH, 2022, vol. 19, issue 3, 1-15

Abstract: Both acute and chronic kidney diseases substantially contribute to the morbidities and mortality of patients worldwide. The existing therapeutics, which are mostly developed from synthetic sources, present some unexpected effects in patients, provoking researchers to explore potential novel alternatives. Natural products that have protective effects against various renal pathologies could be potential drug candidates for kidney diseases. Mangiferin is a natural polyphenol predominantly isolated from Mangifera indica and possesses multiple health benefits against various human ailments, including kidney disease. The main objective of this review is to update the renoprotective potentials of mangiferin with underlying molecular pharmacology and to highlight the recent development of mangiferin-based therapeutics toward kidney problems. Literature published over the past decade suggests that treatment with mangiferin attenuates renal inflammation and oxidative stress, improves interstitial fibrosis and renal dysfunction, and ameliorates structural alteration in the kidney. Therefore, mangiferin could be used as a multi-target therapeutic candidate to treat renal diseases. Although mangiferin-loaded nanoparticles have shown therapeutic promise against various human diseases, there is limited information on the targeted delivery of mangiferin in the kidney. Further research is required to gain insight into the molecular pharmacology of mangiferin targeting kidney diseases and translate the preclinical results into clinical use.

Keywords: chronic kidney disease; renoprotective; kidney fibrosis; oxidative stress; inflammation; mangiferin (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/3/1864/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/3/1864/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:3:p:1864-:d:743870

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().